Perceptive Advisors’s BioLineRX BLRX Stock Holding History

Perceptive Advisors’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-276	Closed	-$345K	–	126
2014 Q2	$345K	Sell	276 -22	-7%	-$27.5K	0.03%	90
2014 Q1	$399K	Buy	+298	New	+$490K	0.04%	96

Other funds holding BLRX

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

NFG

Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Perceptive Advisors's BLRX Position: Q3 2014 in Review

Perceptive Advisors sold out of BioLineRX (BLRX) in Q3 2014, closing a stake of 276 shares — an estimated $345K sold.

Perceptive Advisors first reported a position in BLRX in Q1 2014 and held it in 2 quarters. The position peaked at $399K in Q1 2014. 15 funds tracked by Wall St. Rank hold BLRX as of Q3 2014.

Perceptive Advisors reported no remaining BioLineRX position as of Q3 2014 after selling out during the quarter.
Perceptive Advisors sold 276 BioLineRX shares in Q3 2014, an estimated $345K.
Perceptive Advisors first reported a position in BioLineRX in Q1 2014 and held it in 2 quarters.
Perceptive Advisors's BioLineRX position peaked at $399K in Q1 2014.
15 funds tracked by Wall St. Rank held BioLineRX as of Q3 2014.

Based on Perceptive Advisors's 13F filing for Q3 2014, filed 14 Nov 2014.